Bullish & Foolish
Full MIRA fundamentals All 466 on the Survival Watch

MIRAMIRA Pharmaceuticals, Inc.

Is MIRA Pharmaceuticals struggling financially?

Yes, by its own account. MIRA Pharmaceuticals told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

20/100

Fragile

Sector
Biotech/Pharma
Market cap
$32.1M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 10months

    If the burn speeds up

    Empty by Apr 2027

  • 14months

    If it eases off

    Empty by Aug 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$8.1M

÷

Cash burned over the last 12 months

$8.3M

What MIRA Pharmaceuticals told the SEC

…hand to support its operations for at least the 12 months following the date these unaudited condensed financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Quarterly Report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or…

MIRA Pharmaceuticals, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 141.8% share-count increase The company issued stock. Each share now owns 58.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt